Harvard Bioscience (NASDAQ:HBIO) Share Price Crosses Below 200-Day Moving Average of $4.50

Harvard Bioscience, Inc. (NASDAQ:HBIOGet Free Report) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.50 and traded as low as $4.24. Harvard Bioscience shares last traded at $4.27, with a volume of 54,335 shares trading hands.

Harvard Bioscience Price Performance

The stock has a market cap of $185.32 million, a PE ratio of -53.37 and a beta of 1.43. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.85 and a quick ratio of 0.92. The business has a fifty day moving average of $4.55 and a 200 day moving average of $4.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lazard Asset Management LLC lifted its holdings in Harvard Bioscience by 230.5% during the 1st quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 4,966 shares during the last quarter. Barclays PLC bought a new position in Harvard Bioscience during the 2nd quarter worth approximately $43,000. BNP Paribas Arbitrage SA lifted its holdings in Harvard Bioscience by 47.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 3,200 shares during the last quarter. Prudential Financial Inc. bought a new position in Harvard Bioscience during the 2nd quarter worth approximately $37,000. Finally, State Board of Administration of Florida Retirement System bought a new position in Harvard Bioscience during the 2nd quarter worth approximately $61,000. Institutional investors own 76.06% of the company’s stock.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Featured Stories

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.